Tolerability challenges have been identified with tumor necrosis factor (TNF) antagonist therapy in the treatment of rheumatoid arthritis ... including both non-biologic DMARDs such as MTX ...

Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate response or intolerable adverse events. Evidence from observational studies and ...

Medically reviewed by Stella Bard, MD Osteoarthritis (OA) and rheumatoid arthritis (RA) are two of the most common types of ...

Identify triggers, recognize symptoms, and manage RA flare-ups effectively with lifestyle, medication, and support for better ...

Rheumatoid Arthritis Awareness Day 2025 is observed on February 2. Created in 2013 by the Rheumatoid Patient Foundation, it is to raise awareness around the chronic autoimmune disease. Rheumatoid ...

Rheumatoid arthritis (RA) is a chronic autoimmune condition that affects millions worldwide. According to the World Health Orgnization, 18 million people worldwide were living with the condition in ...

“Asthma and rheumatoid arthritis (RA) are both prevalent diseases ... oral corticosteroids, biologics and azathioprine. Ramonell and Wenzel called these findings that eight of nine patients ...

The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...

A link between rheumatoid arthritis and appendicitis has been investigated before, but newer research has not confirmed these findings. Rheumatoid arthritis is an autoimmune disease where the ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...